These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2544850)
1. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. Blennow M; Granström M Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850 [TBL] [Abstract][Full Text] [Related]
2. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine. Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522 [TBL] [Abstract][Full Text] [Related]
3. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Blennow M; Granström M; Jäätmaa E; Olin P Pediatrics; 1988 Sep; 82(3):293-9. PubMed ID: 3043367 [TBL] [Abstract][Full Text] [Related]
4. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348 [TBL] [Abstract][Full Text] [Related]
5. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination. Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002 [TBL] [Abstract][Full Text] [Related]
6. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children. Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants. Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA; Meschievitz C Pediatrics; 1993 Apr; 91(4):756-60. PubMed ID: 8464662 [TBL] [Abstract][Full Text] [Related]
9. Diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP): response to varying immunizing dosage and schedule. Barkin RM; Samuelson JS; Gotlin LP Dev Biol Stand; 1985; 61():297-307. PubMed ID: 2872117 [TBL] [Abstract][Full Text] [Related]
10. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702 [TBL] [Abstract][Full Text] [Related]
11. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809 [TBL] [Abstract][Full Text] [Related]
12. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Halperin SA; Mills E; Barreto L; Pim C; Eastwood BJ Pediatr Infect Dis J; 1995 Sep; 14(9):792-7. PubMed ID: 8559630 [TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. Keitel WA; Muenz LR; Decker MD; Englund JA; Mink CM; Blumberg DA; Edwards KM J Infect Dis; 1999 Aug; 180(2):397-403. PubMed ID: 10395855 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973 [TBL] [Abstract][Full Text] [Related]
15. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026 [TBL] [Abstract][Full Text] [Related]
16. A modified schedule for routine pertussis immunization. Swartz TA; Roumiantzeff M; Peyron L; Stopler T; Kanaaneh H; Leitner L; Goldblum N Dev Biol Stand; 1985; 61():289-96. PubMed ID: 2872116 [TBL] [Abstract][Full Text] [Related]
17. Results with a new DTP vaccine in Japan. Kimura M; Hikino N Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Gustafsson L; Hessel L; Storsaeter J; Olin P Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988 [TBL] [Abstract][Full Text] [Related]
19. Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Edwards KM; Decker MD; Bradley RB; Taylor JC; Hager CC Pediatr Infect Dis J; 1991 Apr; 10(4):315-8. PubMed ID: 2062628 [TBL] [Abstract][Full Text] [Related]